Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA1/2 Mutation - SOLI Study

Next Previous
Trial Profile

A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA1/2 Mutation - SOLI Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; HER2 negative breast cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms SOLI
  • Sponsors AstraZeneca

Most Recent Events

  • 28 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 12 Apr 2022 Status changed from recruiting to active, no longer recruiting.
  • 02 Jun 2021 Planned End Date changed from 31 Dec 2021 to 31 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top